Less Time in the Hospital: Real-World Benefits of Venetoclax for AML Patients | Aaron Goldberg, MD | #EHA2025

Less Time in the Hospital: Real-World Benefits of Venetoclax for AML Patients | Aaron Goldberg, MD | #EHA2025

Promising New Combo Treatment Shows High Remission Rates in AML Patients with NPM1 and KMT2A Mutations | Harry Erba, MD | #EHA2025

Promising New Combo Treatment Shows High Remission Rates in AML Patients with NPM1 and KMT2A Mutations | Harry Erba, MD | #EHA2025

Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA2025

Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA2025

Skip navigation Search Create Avatar image Implementation of Hospital-Level Care at Home for Acute Leukemia | Nikesh Shah, MD | #EHA 2025

Implementation of Hospital-Level Care at Home for Acute Leukemia | Nikesh Shah, MD | #EHA 2025

New Advances in Treating Acute Lymphoblastic Leukemia | Mark Litzow, MD | #EHA 2025

New Advances in Treating Acute Lymphoblastic Leukemia | Mark Litzow, MD | #EHA 2025

Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025

Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025

Improved Survival in Young B-ALL Patients with Blinatumomab | Mark Litzow, MD | #EHA 2025

Improved Survival in Young B-ALL Patients with Blinatumomab | Mark Litzow, MD | #EHA 2025

Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025

Racial Disparities in CLL Treatment: What the Latest Data Tells Us | Adam Kittai, MD | #EHA 2025

Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025

Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025

What immunotherapies are used in myeloma?

Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25

Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25